|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue: | |||||
| Total revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general, and administrative | |||||
| Goodwill and intangible assets impairment | |||||
| Goodwill impairment | |||||
| Long-lived assets impairment | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Royalty liability interest expense - related parties | |||||
| Other interest income, net | |||||
| Non-operating income, net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Net loss attributable to redeemable noncontrolling interest | |||||
| Net loss attributable to noncontrolling interest and redeemable noncontrolling interest | |||||
| Net loss attributable to Cibus, Inc. stockholders | |||||
| Basic net loss per share of Class A common stock (in dollars per share) | |||||
| Diluted net loss per share of Class A common stock (in dollars per share) | |||||
| Weighted average shares of Class A common stock outstanding - basic (in shares) | |||||
| Weighted average shares of Class A common stock outstanding - diluted (in shares) | |||||
| Anti-dilutive stock options, restricted stock units, performance stock units, and common stock warrants | |||||
Loading...